Format

Send to

Choose Destination
J Neurooncol. 2009 Jan;91(1):47-50. doi: 10.1007/s11060-008-9676-4. Epub 2008 Aug 19.

Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.

Author information

1
Department of Medical Oncology, Spedali Civili di Brescia, Brescia, Italy. franzval@yahoo.it

Abstract

We report the case of a 75-year old woman who received sorafenib (Nexavar), Bayer Pharmaceuticals Corporation, West Haven, CT) for a CNS relapse of clear cell renal cell carcinoma. After four months of sorafenib treatment, a brain magnetic resonance imaging showed 95%-volumetric regression of cerebral metastasis. To the best of our knowledge, this is the first almost complete resolution of brain metastases in renal cell carcinoma treated with sorafenib that has been described.

PMID:
18712279
DOI:
10.1007/s11060-008-9676-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center